Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience

Creative Commons License

Tatar B., Kose S., Ergun N. C., Turken M., ÖNLEN Y., YILMAZ Y., ...More

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, vol.65, no.12, pp.1470-1475, 2019 (SCI-Expanded) identifier identifier identifier


OBJECTIVE: The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice.